T cell therapy for nasopharyngeal carcinoma.

Among the novel biologic therapeutics that will increase our ability to cure human cancer in the years to come, T cell therapy is one of the most promising approaches. However, with the possible exception of tumor-infiltrating lymphocytes therapy for melanoma, clinical trials of adoptive T-cell therapy for solid tumors have so far provided only clear proofs-of-principle to build on with further development. Epstein-Barr virus (EBV)-associated malignancies offer a unique model to develop T cell-based immune therapies, targeting viral antigens expressed on tumor cells. In the last two decades, EBV-specific cytotoxic T-lymphocytes (CTL) have been successfully employed for the prophylaxis and treatment of EBV-related lymphoproliferative disorders in immunocompromised hosts. More recently, this therapeutic approach has been applied to the setting of EBV-related solid tumors, such as nasopharyngeal carcinoma. The results are encouraging, although further improvements to the clinical protocols are clearly necessary to increase anti-tumor activity. Promising implementations are underway, including harnessing the therapeutic potential of CTLs specific for subdominant EBV latent cycle epitopes, and delineating strategies aimed at targeting immune evasion mechanisms exerted by tumor cells.

Risk for recombinants in pericentric inversions of the (p11 leads to q21) region of chromosome 18.

A child with female hypospadia complicated by bilateral hydronephrosis, hydroureter, and hydrocolpos was heterozygous for a pericentric inversion of chromosome 18, 46,XX,inv(18)(p11q21). The normal mother and her father had the same inversion. The abnormal phenotype of the girl could be due to undetectable recombination or to a position effect. She had a low level of the enzyme peptidase-A whose locus is on 18q, while her mother and grandfather had normal levels. The two other cases of familial inversions for chromosomes 18 in the literature both involve the same (p11 leads to q21) region. These three families give a tentative figure of at least 10% as the risk for a normal carrier of this pericentric inversion to have an affected offspring due to recombination.